Jump to content

Moderna’s share price on watch ahead of Q3 earnings


Recommended Posts

Moderna’s share price is down close to 40% year-to-date, as Covid-19 risks took a backseat. What can we look forward to in the upcoming Q3 results?

bg_moderna_370122325.jpgSource: Bloomberg

 Yeap Jun Rong | Market Strategist, Singapore | Publication date: Thursday 27 October 2022 

When does Moderna report earnings?

Moderna is set to release its third-quarter (Q3) financial results on 3 November 2022, before market open. Current expectations are for its Q3 revenue to fall 29.0% from a year ago at US$3.5 billion. This will also mark the third consecutive quarterly decline. Earnings per share (EPS) is expected to come in at $3.29, a 57.2% decline from a year ago.

Still seeking a catalyst after Covid-19

With Moderna previously riding on the Covid-19 waves, abating virus risks in its key markets such as US and Europe have driven an ongoing moderation in its profits since its peak in Q4 2021. More than 70% of the total population in US and Europe has already been fully vaccinated and that leaves Moderna having to seek vaccine sales outside of those regions. That has not played out well thus far, with Moderna’s second-quarter (Q2) revenue outside of US and Europe contracting by 42% quarter-on-quarter. Lower-priced vaccine alternatives, the relative strength of the US dollar and less emphasis on vaccination with economic reopening could be reasons for the low take-up rate.

The emergence of new Covid-19 sub-variants such as BQ.1 and BQ1.1 may call for the need for updated vaccine booster shots, but unless new sub-variants proved to be significantly more deadly and more resistant to currently available vaccines, the take-up rate for additional booster shots could still be lukewarm. Addressable market size could be more dependent on the elderly population and even then, it will have to take much more to convince markets that its growth can be sustainable. To top it off, the US government has announced to stop buying Covid-19 vaccines as early as this November and will remove the free distribution of Covid-19 shots starting next year, leaving Covid-19 product manufacturers to compete in the private markets.

Chart 1: Share of people vaccinated against Covid-19Source: Our World in Data


Pressure is on for other new innovative commercial developments

The pressure is clearly on for Moderna to diversify away from Covid-19 vaccines, which it is currently still heavily dependent on. A key unique selling point for the success of Moderna’s vaccines against Covid-19 is its mRNA technology, which has the potential to be replicated to develop other forms of vaccines. The company is currently in the midst of developing a deal with the US government to develop vaccines against a range of biological threats, including Ebola. Pharmaceutical giant, Merck & Co, has also paid Moderna US$250 million to co-develop a vaccine for returning skin cancer. With its overseas operations revolving around research in other vaccine developments for infectious diseases, cancer and rare disease, further tie-up and collaboration could be in the pipeline.

That said, as with all forms of research and development efforts, it comes with prolonged expenses, risks of failure and could take years to materialise (and monetize). The US$7.9 billion cash pool in the company does provide some runway for Moderna to tap on, but if a trend is formed for a constant drawdown (as with past two quarters), that could still drive some caution.

Technical analysis: Breakout of ranging pattern may be needed

Moderna’s share price has been largely trading in a ranging pattern since the start of the year, with the flat-lined moving average convergence/divergence (MACD) revealing an ongoing period of indecision. A clear catalyst to drive further moves could be much needed, as trading volume has not been heading lower ever since hitting its peak in August 2021. Trading within the range will leave near-term support at the US$116.00 level, while resistance could be presented at the upper consolidation range at the US$200.00 level. It may seem that a move above the US$200.00 level could be necessary to indicate a trend reversal and open the path to the US$263.00 level next.

SGX_Moderna_271022.jpgSource: IG Charts

On the lower four-hour timeframe, Moderna’s share price is currently finding resistance at the US$148.00 level, with a bearish rejection presented in the formation of a shooting star candle. Overcoming this level could drive a retest of the US$158.40 level of resistance next.

SGX_Moderna2_271022.jpgSource: IG Charts
Link to comment

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
  • General Statistics

    • Total Topics
    • Total Posts
    • Total Members
    • Most Online
      10/06/21 10:53

    Newest Member
    Joined 28/09/23 14:16
  • Posts

    • hello, just tried IG sinals Intraday and short term and lost £200 ish.. anyone used them ? any help or feedback ?
    • Dow, Nasdaq 100 and CAC40 struggle in early trading Indices are under pressure again as oil prices and bond yields continue to rise. Source: Bloomberg  Chris Beauchamp | Chief Market Analyst, London | Publication date: Thursday 28 September 2023 11:38 Dow eats into Wednesday’s recovery The index briefly slumped to its lowest level since early June yesterday, heading towards the 33,230 level. A rebound from the lows helped to avoid another weak close but the general bearish move remains firmly in place. More losses target the May lows around 32,700. Buyers will be looking for a move back above 33,827 and the 200-day simple moving average (SMA) to suggest that a low has formed. Intraday movement has been capped by the 50-hour SMA over the past week. Source: ProRealTime Nasdaq 100 bounce fizzles The index managed to eke out a small rally yesterday off the lows, but has struggled to push higher in early trading this morning. This has put the price back above the August low of 14,553, so if this holds buyers may attempt to wrest control and drive the index back towards 15,000. A close back below 14,550 would mark a bearish development, potentially open the way towards the June lows at 14,230. Source: ProRealTime CAC40 stuck below previous support After falling just below the 7100 support zone earlier in the week, the index has managed to avoid any further steep losses for the time being. The March lows at 6900 beckon in the event of a fresh drop, while on the upside 7100 could act as resistance in the short-term now it has been broken as support. A longer-term bullish view would require a close back above 7200. Source: ProRealTime
    • Discover how the ASX 200 fared in September and its prospects for a rebound.   Source: Bloomberg   Indices ASX Inflation Interest rate S&P 500 Australia  Tony Sycamore | Market Analyst, Australia | Publication date: Thursday 28 September 2023 09:18 The ASX 200: a look at September's performance A tough September September has once again lived up to its reputation as the worst month of the year for the ASX 200, currently down 3.68% month to date (MTD) with one full trading session left to go. Mixed performance in 2023 The ASX 200's disappointing performance in September follows a losing month in August (-1.42%), which has conspired to see the ASX 200 trading flat on the year (excluding dividends). The Australian bourse has returned a meager 3.5% in 2023 if dividends are included. A return that seems incomprehensible after the ASX 200 leaped from the starting blocks, adding a rapid-fire 6.22% in January on optimism around the China reopening and hopes that the headwinds of rising interest rates and inflation encountered in 2022 were in the rearview mirror: most of which we now know were unfounded. ASX 200 vs. global indices The reopening in China faded soon after, and still, three-quarters of the way through the year remains elusive. Interest rates, particularly at the long end of the curve, have raced higher both domestically and abroad. The jury remains out as to whether central banks have tightened policy enough to bottle the inflation genie. Optimists may point out that the ASX 200 has outperformed in September relative to US indices, given that both the S&P 500 and the NASDAQ are down over 5% MTD. However, that would overlook the fact that an index with a similar makeup to Australia’s, the FTSE 100, with its large weighting of miners, financial, and energy stocks, is on track for a positive month and a positive quarter. ASX 200 sector analysis At a sector level, all 11 ASX sectors appear poised to close lower for the month. The interest-sensitive real estate and IT sectors have been the main casualties, currently down by -6.57% and -5.46% MTD respectively The healthcare sector, representing 10.06% of the index, has declined by -4.58% in September The materials sector, accounting for a substantial 23.8% weighting within the index, has fallen by -3.16% in September The financial sector, comprising 27.1% of the index, is down by -0.37% in September The energy sector, making up 6.3% of the index, has been the best-performing sector this month. However, despite the price of crude oil surging by over 13% in September, the ASX 200 energy sector is down by -0.17% MTD. ASX sector breakdown chart   Source: SPGlobal.com ASX technical analysis The ASX 200 has spent the bulk of this year trading sideways in a range, above year-to-date lows at 6900 and below year-to-date high at 7567, struck in early February. The sideways price action in 2023 appears corrective and follows an impulsive five-wave rally (Elliott Wave) from the October 2022 double low at 6411 to the 7567 high of February this year. With the ASX 200 trading towards the bottom of its range, combined with the S&P 500 cash reaching our 4250/00 pullback target, we turn tactically bullish on the ASX 200, looking for a return to range (7440) highs and possibly year-to-date highs (7567). Stops on the bullish view would be if the ASX 200 were to see a sustained close below 6900, aware that should support at 6900 give way, the risks are for a test of 6750 before the 2022 lows at 6400. ASX 200 daily chart   Source: TradingView   TradingView: the figures stated are as of September 28, 2023. Past performance is not a reliable indicator of future performance. This report does not contain and is not to be taken as containing any financial product advice or financial product recommendation.         This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.
  • Create New...